Phase III Trial Comparing Fulvestrant and Capecitabine as Maintenance Treatment After First-Line Chemotherapy in Women With Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Led by Herui Yao · Updated on 2022-09-30
210
Participants Needed
13
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of two maintenance treatments, fulvestrant and capecitabine, for women with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer. This phase III trial compares these options after patients have completed first-line chemotherapy. The goal is to determine which treatment better delays disease progression while maintaining quality of life.
Participants receive either fulvestrant injections at specific intervals days 0, 14, 28, then every 28 days or capecitabine orally in cycles of 14 days on treatment followed by 7 days off. The study is randomized and open-label, involving multiple centers. The trial includes a treatment period with ongoing monitoring for adverse events and quality of life.
During the study, participants undergo imaging tests to assess tumor status before starting maintenance therapy, along with regular blood tests and liver and kidney function checks. Researchers track progression-free survival over an estimated 18 months and evaluate overall survival, response rates, clinical benefit, and quality of life up to five years. Safety is monitored from consent through 28 days after treatment ends, ensuring comprehensive participant follow-up.
CONDITIONS
Brief Title
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
Research Team
H
Herui Yao, PhD
W
Wenjing Wu, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Adult female patients aged 18 to 75 years with advanced breast cancer diagnosed by pathology
Hormone receptor-positive (ER and/or PR positive) and HER2-negative breast cancer confirmed by pathology
No disease progression after 4 to 8 cycles of first-line chemotherapy (including capecitabine monotherapy limited to 6 cycles)
WHO physical status score of 0 or 1 with an expected lifetime of at least 3 months
Imaging exams within 3 weeks before enrollment to assess tumor lesions
Previous treatment-related toxicity relieved to Grade 1 or less (except hair loss and non-safety risks)
Normal routine blood tests within 1 week before enrollment
Normal liver and kidney function tests within 1 week before enrollment
Signed informed consent before enrollment
You will not qualify if you...
Newly developed central nervous system metastasis or less than 4 weeks symptom control of CNS metastasis (stable, asymptomatic brain metastases over 4 weeks without corticosteroid use allowed)
Diagnosis of any other malignant tumor within 3 years before randomization, except treated basal or squamous cell skin cancer or cervical cancer in situ
Previous endocrine therapy for advanced disease
Pregnant or breastfeeding women
Serious medical conditions that may affect safety, such as uncontrolled heart disease, high blood pressure, active infection, or active hepatitis B
Previous intolerance to capecitabine toxicity during first-line treatment
Recurrent metastatic disease within 2 years after adjuvant endocrine therapy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Until disease progression or discontinuation
Participants receive maintenance therapy with either fulvestrant injections or oral capecitabine following first-line chemotherapy to delay disease progression.
Fulvestrant group: injections on Days 0, 14, 28, then every 28 days; Capecitabine group: oral medication twice daily for 14 days followed by 7 days off in repeated cycles
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating Safety, Dose, and Effects of BNT323 Combined With BNT327 in Advanced Breast Cancer Patients A Phase III Open-Label Two-Part Study
Phase 1 Study to Evaluate the Safety, Tolerability, and Distribution of 177LuLu-ABY-271 in Women with HER2-positive Metastatic Breast Cancer
Evaluating the TheraBionic P1 Device in Women with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer After Endocrine Therapy
Phase 1 Study of ERX-315 Given by IV Twice Weekly in Adults With Advanced Solid Tumors That Have Not Responded to Standard Treatments
Randomized Phase 3 Trial of HRS-8080 Versus Physician-Selected Treatments in Women With Advanced and Metastatic Breast Cancer After Endocrine Therapy
Phase I Open-Label Trial to Test Safety and Early Effectiveness of Autologous p95HER2.CAR-TECH2Me T Cells in Adults with Advanced HER2-Positive Breast, Gastric, Endometrial, and Other Selected Cancers
Phase III Study of FWD1802 Treatment for Women With ERHER2- Advanced or Metastatic Breast Cancer
Study of Multiple Combination Therapies with FWD1802 for Women with ER-positiveHER2-negative Advanced or Metastatic Breast Cancer
Phase II Study of SSGJ-612 Combined With HER2-Targeted Antibody-Drug Conjugate in Hormone Receptor-Positive, HER2-Low or Ultralow Metastatic Breast Cancer
Phase 3 Study Comparing ESG401 and Physicians Choice Chemotherapy for Adults with Advanced HRHER2- Breast Cancer After Chemotherapy Failure
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.